Investing.com - Financial Markets Worldwide

Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707)

Shanghai
Currency in CNY
11.55
+0.10(+0.87%)
Closed·
603707 Scorecard
Full Analysis
High shareholder yield
Earnings results expected in 10 days
603707 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
11.5011.77
52 wk Range
10.1216.01
Key Statistics
Edit
Bid/Ask
11.55 / 11.56
Prev. Close
11.45
Open
11.5
Day's Range
11.5-11.77
52 wk Range
10.12-16.01
Volume
18.86M
Average Volume (3m)
13.86M
1-Year Change
-1.64%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
603707 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
15.80
Upside
+36.83%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 8
Prominent player in the Pharmaceuticals industry
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Nanjing King-friend Biochemical Pharmaceutical Co Ltd Company Profile

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochloride, ganirelix acetate, furosemide, glycopyrrolate, neostigmine methylsulfate, succinylcholine chloride, reganosin, isoflurane blue, clofarabine, haloperidol decanoate, busulfan, gemcitabine hydrochloride, dexmedetomidine hydrochloride, nelarabine, rocuronium bromide, zoledronic acid, bupivacaine hydrochloride, plerixafor, eptifibatide, fondaparinux sodium, docetaxel, fluorouracil, palonosetron hydrochloride, oxaliplatin, fulvestrant, and adalimumab injections. The company offers bortezomib, bendamustine hydrochloride, mycophenolate mofetil, vancomycin hydrochloride, daptomycin, decitabine, voriconazole, tigecycline, melphalan hydrochloride, actinomycin, micafungin, azacitidine, pantoprazole sodium, mitomycin, pemetrexed disodium, thiotepa, and dacarbazine for injections. Its injection products cover anticoagulation, anti-tumor, cardiovascular disease, as well as surgical anesthesia, anti-bacterial infection, and angiography. Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. was founded in 2000 and is headquartered in Nanjing, China.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
1360
Market
China

Compare 603707 to Peers and Sector

Metrics to compare
603707
Peers
Sector
Relationship
P/E Ratio
25.4x25.9x−0.6x
PEG Ratio
0.090.120.00
Price/Book
2.8x2.5x2.6x
Price / LTM Sales
4.9x3.5x3.3x
Upside (Analyst Target)
29.9%7.8%39.1%
Fair Value Upside
Unlock10.6%4.5%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.80
(+36.83% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.45%
Dividend Yield
0.87%
Industry Median 1.50%
Annualised payout
0.10
Paid annually
5-Years Growth
-6.05%
Growth Streak
Unlock

Earnings

Latest Release
Apr 28, 2025
EPS / Forecast
0.05 / --
Revenue / Forecast
885.22M / --
EPS Revisions
a
a
Unlock
Last 90 days

603707 Income Statement

FAQ

What Stock Exchange Does Nanjing King-friend Bio Trade On?

Nanjing King-friend Bio is listed and trades on the Shanghai Stock Exchange stock exchange.

What Is the Stock Symbol for Nanjing King-friend Bio?

The stock symbol for Nanjing King-friend Bio is "603707."

What Is the Nanjing King-friend Bio Market Cap?

As of today, Nanjing King-friend Bio market cap is 18.63B.

What Is Nanjing King-friend Bio's Earnings Per Share (TTM)?

The Nanjing King-friend Bio EPS (TTM) is 0.45.

When Is the Next Nanjing King-friend Bio Earnings Date?

Nanjing King-friend Bio will release its next earnings report on 28 Aug 2025.

From a Technical Analysis Perspective, Is 603707 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Nanjing King-friend Bio Stock Split?

Nanjing King-friend Bio has split 5 times.

How Many Employees Does Nanjing King-friend Bio Have?

Nanjing King-friend Bio has 1360 employees.

What is the current trading status of Nanjing King-friend Bio (603707)?

As of 19 Aug 2025, Nanjing King-friend Bio (603707) is trading at a price of 11.55, with a previous close of 11.45. The stock has fluctuated within a day range of 11.50 to 11.77, while its 52-week range spans from 10.12 to 16.01.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.